Retinoblastoma intravitreal chemotherapy (five-year experience)
DOI:
https://doi.org/10.31288/oftalmolzh201535968Keywords:
retinoblastoma, intravitreal chemotherapy, combined polychemotherapyAbstract
Introduction. Local intravitreal chemotherapy (IVC) is one of the new retinoblastoma (RB) salvage eye methods. However, IVC indications, doses and algorithm of cytostatic application are still not developed, complications and efficacy of this method are not enough studied.
Purpose. To study the short-term and long-term results of IVC in RB complex salvage eye treatment.
Material and methods. IVC was Melphalan was given to 67 children aged 2 -14 y/o (average 19.2±16.5 mo) inn 91 eyes with RB T1 — T3b stages. 2 groups were selected depending on a dose and IVC method: the 1st group (16 eyes) — the dose was 0.015mg of Melphalan in 1 injection secondary in pretreated RB cases, the 2nd group (75 eyes) — the dose was 0.01 mg of Melphalan in 1 injection as primary therapy in combination with systemic chemoreduction [3]. Follow up from 2 to 5 years (average 20.3±9.1 mo) was in 32 patients (42 eyes).
Results. In the 1st group the amount of complications and enucleations was evidence of insufficient efficacy of the second IVC. In this connection the method of combined RB polychemotherapy (PCT) — primary IVC with Melphalan in the dose O.01 mg with simultaneous chemoreduction of CEV-protocol (Patent of Ukraine A61f 9/007 of 27.12.2010) and algorithm of its administration every 3 weeks with additional focal tumor destruction if necessary was developed. Complications were practically not observed except local retinal degeneration in the injection areas (15 eyes). 78.6 % of the eyes were preserved: in the T1-T2 stages — 100 %, T3 (including T3a-T3b) — 65.4 %.
Conclusion. Due to our five-year’s experience the developed method of primary IVC in combination with systemic Carboplatin PCT gives the greatest chance for eye and sight preservation with minimal amount of complications and cytostatic drug local and general toxic influence.
References
Avetisov ES, Kovalevskii EI, Khvatova AV. Guidelines for Pediatric Ophthalmology. M.: Meditsina; 1987. 496 p.
Bobrova NF, Sorochinskaia TA. New trends in the treatment of retinoblastoma in children. Proceedings of International Scient. Conf. Боброва Н. Ф. ded. to 100th Ann. Of N. A. Puchkovskaia, Odessa. 2008. 25-60. In Russian.
Bobrova N. F. The method of combined treatment of retinoblastoma. Potent of Ukraine 55690 U from 27.12.2010
Saakyan S. V. Modern approaches of treatment for retinoblastoma. Rossiiskii Ofatalmol Zhurnal. 2008;1:33-8. In Russian.
Bobrova NF, Sorochinskaya TA. Local retinoblastoma chemotherapy by intravitreal Melphalan injections (the preliminary report). SE Eur J Ophthalmol. 2009;2 (3-4): 28-34.
Chan H, Gallie B, Munier F, Beck Popovic M. Chemotherapy for retinoblastoma. Ophthalmol Clin North Am. Mar 2005;18(1):55-63 https://doi.org/10.1016/j.ohc.2004.11.002
Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res.2009;26:1236-1260.https://doi.org/10.1007/s11095-008-9728-7
Edelhauser HF, Boatright JH, Nickerson JM and the Third ARVO/Pfizer Research Institute Working Group. Drug delivery to posterior intraocular tissues: third annual ARVO/Pfizer ophthalmics research institute conference. Invest Ophthalmol Vis Sci. 2008;49:4712-4720 https://doi.org/10.1167/iovs.08-1904
Edelhauser HF, Rowe-Rendleman C, Robinson M et al. Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Applications. Investigative Ophthalmology & Visual Science. 2010;51(11):5403-5420.https://doi.org/10.1167/iovs.10-5392
Ericson LA, Rosengren BH. Present therapeutic resources in retinoblastoma. Acta Ophthalmol. 1961;39:569-576.https://doi.org/10.1111/j.1755-3768.1961.tb00269.x
Frederici TJ. Intravitreal injections: AAO's Focal Points. Clinical Modules for Ophthalmologists. 2009;27(8, module 2):1-12.
Gallie B, Budning A, DeBoer G et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. //Arch Ophthalmol. Nov 1996;114(11):1321-1328.https://doi.org/10.1001/archopht.1996.01100140521001
Gallie B, Gronsdahl P, Dimaras H et al. National Retinoblastoma Strategy Canadian Guidelines for Care. Can J Ophthalmol. 2009;44, Suppl. 2:S9 https://doi.org/10.3129/i09-194
Ghassemi F, Shields C. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130:1268-1271. https://doi.org/10.1001/archophthalmol.2012.1983
Ghate D, Edelahauser HF. Ocular drug delivery. Expert Opin Drug Deliv. 2006;3:275-287. https://doi.org/10.1517/17425247.3.2.275
Gobin Y, Dunkel J, Marr BP. Combined, Sequential Intravenous and Intra-Arterial Chemotherapy (Bridge Chemotherapy) for Young Infants with Retinoblastoma.PLOS ONE www.plosone.org. 2012; 7(9). https://doi.org/10.1371/journal.pone.0044322
Gombos D, Hungerford J, Abramson D et al. Secondary acute myelogenousleukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. Jul 2007;114(7):1378-1383.https://doi.org/10.1016/j.ophtha.2007.03.074
Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res. 1987;78: 858-868.
Jager RD, Aiello LP, Patel SC, Cunningham ET. Risks of intravitreous injection: a comprehensive review. Retina. 2004, 24: 676-698 https://doi.org/10.1097/00006982-200410000-00002
Kaneko A, Suzuki S. Eye-Preservation Treatment of Retinoblastoma with Vitreous Seeding. Japanese Journal of Clinical Oncology. 2003; 33: 601-607.https://doi.org/10.1093/jjco/hyg113
Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res.2007;39:244-254.https://doi.org/10.1159/000108117
Kivel? T, Eskelin S, Paloheimo M. Intravitreal methotrexate for retinoblastoma. Ophthalmology. 2011;118(8). - P. 1689.https://doi.org/10.1016/j.ophtha.2011.02.005
Lambert M, Shields C, Meadows A. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 2008;50:223- 6.https://doi.org/10.1002/pbc.21155
Le Goff MM, Bishop PN. Adult vitreous structure and postnatal changes. Eye. 2008;22:1214-1222.https://doi.org/10.1038/eye.2008.21
Munier FL, Gaillard MC, Balmer A, Beck-Popovic M. Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives. Saudi Journal of Ophthalmology. 2013; 27:147-150.https://doi.org/10.1016/j.sjopt.2013.06.003
Munier FL, Gaillard MC, Soliman S et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078-1083.https://doi.org/10.1136/bjophthalmol-2011-301450
Munier FL, Soliman S, Moulin A et al. Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilization of the needle track. Br J Ophthalmol. 2012; 96(8):1084-1086.https://doi.org/10.1136/bjophthalmol-2011-301016
Murphree A, Villablanca J, Deegan W et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1348-56.https://doi.org/10.1001/archopht.1996.01100140548005
Rizzuti A, Dunkel I, Abramson D. The adverse events of chemotherapy for retinoblastoma: what are they? Do we know? Arch Ophthalmol 2008;126:862-5.https://doi.org/10.1001/archopht.126.6.862
Rodriguez-Galindo C, Chantada GL, Haik BG, Wilson MW. Treatment of retinoblastoma: current status and future perspectives. Curr Treat Options Neurol. 2007 Jul;9(4):294-307.https://doi.org/10.1007/s11940-007-0015-4
Rodriguez-Galindo C, Wilson M, Haik B et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003;21:2019-25.https://doi.org/10.1200/JCO.2003.09.103
Seregard S, Kock B, Trampe E. Intravitreal chemotherapy for recurrent retinoblastoma in an only eye. Br J Ophthalmol. 1995;79:194-195.https://doi.org/10.1136/bjo.79.2.194
Shah N, Pham D, Murray Tet al. Intravitreal and Subconjunctival Melphalan for Retinoblastoma in Transgenic Mice. Journal of Ophthalmology. 2014;1-9.https://doi.org/10.1155/2014/829879
Shields C, De Potter P, Himelstein B et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1330-8.https://doi.org/10.1001/archopht.1996.01100140530002
Shields C, Fulco E, Arias J et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye. 2013; 27(2): 253-264.https://doi.org/10.1038/eye.2012.175
Shields C, Mashayekhi A, Cater J et al. Macular Retinoblastoma Managed With Chemoreduction. Analysis of Tumor Control With or Without Adjuvant Thermotherapy in 68 Tumors. Arch Ophthalmol. 2005;123:765-773 https://doi.org/10.1001/archopht.123.6.765
Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-77 https://doi.org/10.1200/JCO.1999.17.2.569
Smith SJ, Pulido JS, Salom?o DR et al. Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds // Br J Ophthalmol. 2012;96(8):1073-1077. https://doi.org/10.1136/bjophthalmol-2011-300829
Smith SJ, Smith BD. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013 Oct;97(10):1231-6. https://doi.org/10.1136/bjophthalmol-2013-303188
Smith SJ, Smith BD, Mohney BG. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2014 Mar; 98(3):292-7. https://doi.org/10.1136/bjophthalmol-2013-303885
Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol. 2004 Feb;9(1):1-6. https://doi.org/10.1007/s10147-003-0366-0
Ueda M, Tanabe J, Inomata M et al. Study on conservative treatment of retinoblastoma - effect of intravitreal injection of melphalan on the rabbit retina. Nihon Ganka Gakkai Zasshi. 1995; 99(11):1230-1235.
Wilson MW, Rodriguez-Galindo C, Haik BG, et al: Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology 108:2106-2115, 2001 https://doi.org/10.1016/S0161-6420(01)00805-3
Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. //Int J Clin Oncol. 2004 Apr;9(2):69-73. https://doi.org/10.1007/s10147-004-0392-6
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Н. Ф. Боброва, Т. А. Сорочинская
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
